Improving Outcomes for Cardiopulmonary Patients

As your speciality care provider, NuvoAir reduces exacerbations, lowers costs, and creates a better care experience for patients with cardipulmonary conditions through our integrated, virtual-first care model.

Value-Based Care, Delivered at Scale

Personalized programs

We tailor clinical programs to members' unique needs, based on their motivations and risk factors.

Clinically relevant data

Our devices continuously and remotely collect biomarkers to empower the best clinical decisions.

Virtual clinic

Our interdisciplinary care team conducts timely clinical interventions whenever patients need help or signals in the data indicate concern.

Exacerbation prevention

Our analytics engine drives the next best action in our clinical model to predict and prevent exacerbations.

Proven Results

Our virtual-first care solution effectively engages and manages people with COPD and comorbidities.

80% Decrease in hospitalizations
60% Decrease in exacerbations
87% Improved quality of life
NPS 60 Net promoter score
NPS 60 High patient satisfaction
80% Reduction in hospital visits
87% Improved quality of life

*Based on patient reported outcomes from a 2021-2022 pilot with rural patients at a primary care clinic in Kentucky and a pulmonary specialty clinic in Indiana.

Why NuvoAir?

Deep experience and engagement across disease areas

Robust data

Over 12k patients served, 1.5 million data points generated

Disease Areas

Providing care for patients suffering from COPD, asthma or Cardiovascular/CHF diseases

Validated evidence

40+ publications validating our clinical solution and patient experience

Outcomes

70% engagement post 1 year
80% reduction hospitalizations
60% reduction in exacerbations

High NPS Score

Patient experience and satisfaction score of 60

Learn more about how NuvoAir can support your cardiopulmonary care needs

Our team will reach out to share more information about our virtual-first specialty care model.

We'll never share your email with anyone else.